21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
20:07 , Apr 26, 2019 |  BC Week In Review  |  Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

Viva would raise HK$1.4 billion ($172.2 million) and be valued at HK$5.9 billion ($748.7 million) if the drug discovery services company prices its Hong Kong IPO at the midpoint of the range it proposed April...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
22:44 , Jan 7, 2019 |  BC Extra  |  Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
23:03 , Nov 2, 2018 |  BioCentury  |  Finance

Innovent’s Hong Kong spark

A strong performance out of the gate for Innovent Biologics Inc. (HKSE:1801) reflects investor confidence in the company’s pipeline regardless of market conditions. The biologics company raised HK$3.3 billion ($421 million) in an IPO priced...
00:17 , Sep 15, 2018 |  BioCentury  |  Finance

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...